Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy and safety of different treatment regimens of rituximab (MabThera®/Rituxan®), corticosteroids, and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genentech, Inc.
• Collaborator: Roche Pharma AG
• Treatments: Methotrexate; Rituximab

Criteria

Eligibility criteria include, but are not limited to the following:

• Are between the ages of 18 and 80 years.

• Have been diagnosed with rheumatoid arthritis for at least 6 months.

• Have failed treatment (lack of efficacy) with at least 1 but no more than 5 disease-modifying anti-rheumatic drugs or biologics (other than methotrexate).